Body Vision Medical News
13 articles
David Webster Appointed New CEO of Body Vision Medical
David Webster has been appointed as the new CEO of Body Vision Medical, a medical device company specializing in AI-driven imaging for the diagnosis and treatment of endoluminal cancer. The company has gained traction in the U.S. market and is expanding into the European market. Websters appointment comes at a pivotal time for the company. Body Visions technology has proven superior in providing intraoperative image guidance and 3D tool-in-lesion confirmation for lung cancer diagnostics. Webster brings extensive experience in the medical device industry and will lead the commercialization of Body Visions AI-driven imaging technology. The company plans to increase its presence in the U.S. and global markets and explore clinical applications beyond lung cancer.
CustomersExpand
Body Vision Medical Celebrates 1,000th Patient to Benefit from AI-Driven Lung Cancer Diagnostics Imaging
Body Vision Medical has announced that 1,000 patients have benefited from its LungVision system, which provides real-time artificial intelligence imaging for lung cancer diagnostics. The company has FDA and CE approvals and started selling commercially earlier this year. The rapid adoption of the technology by top U.S. institutions demonstrates the importance of tool-in-lesion confirmation for definitive diagnosis. Body Visions mission is to make real-time imaging during diagnostic bronchoscopy an option for every lung patient.
Customers
The new GPS for lung cancer diagnosis
Israeli startup Body Vision Medical has developed software that uses artificial intelligence to improve the accuracy of lung cancer diagnosis. The companys LungVision system combines inputs from bronchoscopes, CT scans, and X-rays to predict the location of tumors in the lungs. The software has been approved by the FDA and has raised accuracy rates from 65% to 85%. The system eliminates the need for CT scans, reducing radiation exposure for patients. Body Vision Medical has already been used in over 500 clinical procedures in lung cancer centers in Israel and the United States.
Customers
Israeli technology detects early-stage cancer 'navigating' inside lungs
Lung cancer treatment co Body Vision raises $20m
Israeli medical device company Body Vision Medical has closed a $20 million Series C financing round. The funds will be used to streamline commercialization and manufacturing activities for Body Visions LungVision 2.0 Platform, which features AI Tomography, fused imaging, cloud-based machine learning, and multi-modality image registration. The platform received FDA clearance in May 2019. Body Vision Medical aims to address the unfulfilled clinical need for early lung cancer diagnostics and treatment.
Investment
Body Vision Medical Receives FDA Clearance for LungVision 2.0 System, a Part of LungVision Platform, Demonstrated at ATS 2019
Body Vision Medical has received FDA clearance to market their LungVision 2.0 System, a medical device specializing in augmented real-time imaging, artificial intelligence, and intra-body navigation. The system allows physicians to plan, visualize, and track endobronchial tools inside radiolucent lesions in real time. The LungVision 2.0 System features real-time tool-in-lesion confirmation and seamless integration of a disposable lung navigation catheter. The company will exhibit the platform at the ATS Annual Meeting 2019. The article does not mention any specific customers, partners, investment or acquisition details, layoffs, or valuation amount. The event described in the article occurred on May 17, 2019.
CustomersPartners
Body Vision Medical Announces the Release of LungVision™
Body Vision Medical, a medical device company, has announced the launch of its LungVision platform for lung cancer diagnostics. The platform utilizes augmented reality and real-time imaging to assist in the diagnosis and treatment of lung cancer. The technology has been praised by medical professionals for its ability to detect peripheral nodules and guide biopsy procedures. The company has conducted clinical trials involving over 400 patients at leading lung cancer centers in the US, demonstrating high levels of safety, accuracy, and diagnostic yield. The launch of the LungVision platform is expected to contribute to the growth and success of Body Vision Medical.
Customers
Lung cancer diagnostic co Body Vision Medical raises $8.5m
Israeli medical device company, Body Vision Medical, has raised $8.5 million in funding. The company specializes in lung cancer diagnostics through augmented real-time intra-body navigation and imaging. The funding will be used to accelerate the commercialization efforts of its FDA approved LungVision system in the US and to extend its product line. Body Vision Medicals founder and CEO, Dorian Averbuch, believes that the LungVision system will facilitate early stage diagnosis of lung cancer and pave the way for minimally invasive transcatheter therapeutics.
Investment
Body Vision Medical Raises $8.5M in Funding - FinSMEs
Body Vision Medical, a medical device company based in Israel, has raised $8.5 million in funding. The funding round was led by Mr. Zohar Gilon, the Chairman of the Board. The company plans to use the funds to accelerate the commercialization efforts of its FDA approved LungVision™ system in the U.S. and expand its product line. Body Vision Medical specializes in augmented real-time fusion imaging, artificial intelligence, and intra-body navigation. The LungVision™ system allows physicians to plan procedures, navigate challenging locations, and localize lesions during biopsies, facilitating early stage diagnosis of lung cancer and minimally invasive transcatheter therapeutics.
Investment
Body Vision Medical Receives FDA Clearance for the LungVision Tool, Part of the LungVision Platform Revolutionizing the Areas of Lung Cancer Diagnostics and Treatment
Body Vision Medical has received clearance from the U.S. Food and Drug Administration to market their LungVision Tool, an affordable lung navigation catheter. This approval allows the company to accelerate commercialization efforts for its LungVision Platform, which provides a real-time solution for early-stage lung cancer diagnostics and treatment procedures. The LungVision System has already been used in over 290 clinical procedures in leading lung cancer centers across the U.S. The company aims to revolutionize the way physicians diagnose and treat peripheral lung lesions.
Customers
Body Vision Medical's LungVision System Merges Pre-Op CT with Intraoperative Imaging
Body Vision Medical has received FDA clearance for its LungVision system, which helps guide lung lesion biopsies and surgeries. The system integrates pre-procedural imaging data, intraoperative 2D imaging, and catheter pathway to improve accuracy. The companys technology can be easily integrated with existing operating room equipment. Results of the first in-human study of the LungVision system will be presented at the American Thoracic Society meeting.
PartnersCustomers
Body Vision Medical Receives FDA Clearance for the LungVision Navigation System, Revolutionizing the Areas of Lung Cancer Detection and Treatment
Body Vision Medical has received clearance from the U.S. Food and Drug Administration to market LungVision, an imaging system that enables accurate real-time navigation and lesion localization during bronchoscopic procedures. LungVision merges intraoperative fluoroscopy with pre-operative high-resolution imaging, allowing physicians to plan, visualize, and track endobronchial tools and radiolucent lesions in real time. The company envisions that LungVision will revolutionize the way physicians diagnose and treat peripheral lung lesions. The first clinical experience with the LungVision System will be presented at the American Thoracic Society meeting. Body Vision Medical is a medical device company specializing in augmented real-time imaging.
Customers
Intra-body imaging co Body Vision maps lung cancer
Body Vision Medical, a startup founded by CEO Dorian Averbuch, is active in intra-body imaging using computer vision and augmented reality. The company aims to develop a product that will make it easier to pinpoint and remove small lung tumors. Body Vision has raised $10 million to date from investors including Zohar Gilon, Ari Steimatzky, and Israel Tauber. The company has already carried out 120 imaging procedures in the US as part of a clinical trial and plans to establish a sales set-up in the US in the next year or two.
Investment
